Nuravax
CompanyUnited States
Nuravax develops 2 assets, the furthest in phase 2 (AV-1959R in Alzheimer's disease). Mostly vaccine acting on proteostasis, APP and MAPT; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 2
- 2
- Grants
- 0
- Trials
- 7
- Signals
Pipeline
2Induces antibodies against amyloid-beta to promote clearance and reduce brain amyloid accumulation.
Phase 2, Vaccine, APP, Proteostasis, Alzheimer's disease, preclinical Alzheimer's disease
Investigational preventive vaccine inducing immune responses against pathological tau protein
Phase 1, Vaccine, MAPT, Proteostasis, Alzheimer's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- People1
- Signals7
- Similar companies6